Financial Data and Key Metrics Changes - Total revenue for 2025 grew 29% to $96 million, landing at the high end of guidance, which was raised twice in the second half of the year [6][14] - Adjusted EBITDA increased to $25 million or 26% of revenue, up from $13 million or 18% in 2024 [6][18] - Adjusted net income for Q4 was $1.9 million, compared to an adjusted net loss of $0.1 million in Q4 of the prior year [17] Business Line Data and Key Metrics Changes - In Q4, total revenue reached $24.8 million, increasing 20% year-over-year, primarily driven by the biopreservation media (BPM) franchise [7][14] - BPM product line accounted for approximately 85% of total revenue, with commercial BPM customers accounting for nearly 50% of revenue, up from the low 40s range in 2024 [7][8] - Full year growth across all product lines except hPL media, which was flat year-over-year due to import restrictions in China [15] Market Data and Key Metrics Changes - BioLife's BPM products are embedded in 16 approved therapies and utilized in over 250 commercially sponsored CGT trials in the U.S., representing over 70% market share [8] - Anticipation of up to 5 unique therapy approvals over the next 12 months, along with 1 new indication and at least 1 geographic expansion [9] Company Strategy and Development Direction - The company aims to drive sustainable, profitable growth and shareholder value with a streamlined portfolio centered on market-leading consumables [5] - Focus on expanding role within clinical and commercial programs beyond biopreservation media, with cross-sell opportunities expected to increase revenue per patient dose by 2 to 3 times [9][10] - Strategic distribution and product development agreement with Qkine Limited to expand product offerings in cytokines [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the cell and gene therapy (CGT) market, supported by encouraging clinical data and strategic investments by large pharma [12] - Guidance for 2026 includes revenue between $112 million and $115 million, reflecting growth of 17%-20% [11][20] - Expectation of full year positive GAAP net income for the first time in many years, along with further expansion of adjusted EBITDA margins [21] Other Important Information - Cash and marketable securities balance at December 31, 2025, was $120.2 million, up from $105.4 million at December 31, 2024 [19] - The company implemented ERP manufacturing modules to enhance operational efficiency [14] Q&A Session Summary Question: Guidance assumptions between commercial and clinical - Management expects commercial customers to represent 50%-55% of total revenue in 2026, with no significant uptick in clinical customer orders observed [25] Question: Bag yield impact on margins - Management indicated a 2 to 3-point headwind on gross margin in the second half of 2025 due to bag yield issues, with improvements expected by Q4 2026 [27] Question: Exposure to CAR T market - Over 80% of commercial exposure is related to CAR T therapies, with patient access being a key constraint to growth [33] Question: Cross-selling initiative success - Growth from non-BPM tools is expected to outpace BPM growth, with metrics on customer usage of multiple products being a future goal [40] Question: Partnership with Qkine - The partnership is seen as a long-term strategic move, with revenue expected to materialize in 2026 [46] Question: Potential acquisitions in biopreservation - Management is monitoring potential acquisitions but has not identified any that provide a competitive advantage beyond what is already offered [61]

Financial Performance - In 2025, total revenue grew 29% to $96 million, reaching the high end of guidance, with Q4 revenue at $24.8 million, a 20% year-over-year increase [6][15][16] - Adjusted EBITDA for Q4 was $6.9 million, or 28% of revenue, compared to $3.7 million or 18% in Q4 2024; full year adjusted EBITDA was $25 million or 26% of revenue, up from $13.3 million or 18% in the prior year [19][18] - Adjusted net income for Q4 was $1.9 million, compared to an adjusted net loss of $0.1 million in Q4 2024; full year adjusted net income was $6.3 million, compared to an adjusted net loss of $2.9 million in the prior year [18][19] Business Line Performance - The biopreservation media (BPM) product line accounted for approximately 85% of total revenue, with commercial BPM customers contributing nearly 50% of revenue, up from the low 40s range in 2024 [8][6] - Growth was observed across all product lines except for hPL media, which remained flat due to import restrictions in China [16] Market Dynamics - BioLife's BPM products are embedded in 16 approved therapies and utilized in over 250 commercially sponsored CGT trials in the U.S., representing over 70% market share [9] - The company anticipates up to five unique therapy approvals and one geographic expansion in the next 12 months, indicating a positive regulatory environment [10] Strategic Direction - The company aims to expand its role in clinical and commercial programs beyond biopreservation media, with a focus on cross-selling additional cell processing tools [10][11] - A strategic distribution agreement with Qkine Limited was established to enhance the product offering in cytokines, complementing the emerging hPL product line [12] Management Commentary - Management expressed confidence in the long-term trajectory of the cell and gene therapy (CGT) market, citing favorable macro conditions and increased strategic investments by large pharma [13] - The company expects to achieve full year positive GAAP net income for the first time in many years and further expansion of adjusted EBITDA margins in 2026 [22] Other Important Information - The company implemented ERP manufacturing modules to enhance operational efficiency without disrupting operations [15] - Cash and marketable securities balance at year-end 2025 was $120.2 million, up from $105.4 million at year-end 2024 [20] Q&A Session Summary Question: Can you provide more color on the assumptions between commercial and clinical growth? - Management expects commercial customers to represent 50%-55% of total revenue in 2026, with no significant uptick in clinical customer orders observed yet [25][26] Question: What was the impact of bag yield on margins in the second half of 2025? - Management indicated a 2-3 point headwind on gross margin due to bag yield issues, with solutions expected to be implemented by Q4 2026 [27][28] Question: What is the company's exposure to the CAR-T market? - Over 80% of commercial exposure is related to CAR-T therapies, with patient access being a key constraint to growth [34] Question: Can you elaborate on the cross-selling initiative? - The growth rate of non-BPM tools is expected to outpace BPM tools, with a focus on tracking customer usage of multiple products [41][42] Question: What is the margin profile for the new partnership with Qkine? - Specific margins were not disclosed, but the partnership is viewed as a long-term strategic move rather than a short-term revenue generator [46][48] Question: Are there plans for further acquisitions in biopreservation? - Management is monitoring potential acquisitions but has not identified any that would provide a competitive advantage beyond the recent PanTHERA acquisition [62]